Cambridge, UK; April 8, 2019: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced the appointment of Simon Sturge as its new CEO, effective May 1, 2019. Simon succeeds David Chiswell, who remains a scientific adviser to the Company.
Cambridge, UK, 08 April 2019: Metrion Biosciences (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Andrew Southan as Chief Executive Officer, with immediate effect. Dr Southan was previously the Company’s Chief Operating Officer.
Cambridge, UK, 03 April 2019: TTP plc (TTP), a leading independent technology and product development company, has announced today the formation of Cellular Highways Ltd. The new spin-out has been founded to commercialise TTP’s proprietary Vortex-Actuated Cell Sorting (VACS) technology, and fast-track development of a first commercial product, Highway 1™. TTP has invested £1.7m ($2.2m) in the spin-out, in addition to over £2m development funding to date.
Building on the success of 2018, LabKey will be holding two User Events in Europe in June 2019.
4th and 5th June: Basel Switzerland
6th June: London
The user events are designed to provide a fun and relaxed forum to learn more about what LabKey is and how we help over 500 research institutions around the world to eliminate and address their research data management challenges.
Lonza is to set up a virtual tenancy at Stevenage Bioscience Catalyst (SBC). Through this collaboration, Lonza’s scientific experts will establish a regular presence at SBC working with the Business Development team, joining a vibrant community for biotech growth and development.
No, not an April Fools’ joke - BioBridge Ltd, the Cambridge-based independent life science innovation consultancy, was founded in 1989 and has been at the forefront of biotechnology and life science advances since then, from a ground-breaking report for Frost&Sullivan on biotechnology in animal breeding and production, via helping establish new approaches to xenogeneic therapies and biopharming, to current involvement in the latest green and blue biotechnology advances.
Cambridge, UK, 2nd April: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today confirmed that it has entered into a commercial agreement with Addenbrooke’s hospital, part of Cambridge University Hospitals NHS Foundation Trust, to provide PredictSURE IBD™ to clinicians and gastroenterologists in the UK and Ireland.
Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, announced today that it has completed a fully subscribed funding round on 14 March. Metrion will use the funds to support the broadening of its ion channel screening capabilities, and continued research into novel Kv1.3 inhibitors for the treatment of auto-immune conditions.
Establishes New Clinical Advisory Board of Leading Oncology Experts